Lars Lundin

Specialist physician at Department of Surgical Sciences; Molecular imaging and medical physics

E-mail:: lars.lundin@uu.se
Visiting address:: Akademiska sjukhuset, ingång 70, 1tr
Postal address:: Akademiska sjukhuset, ingång 70, 1tr
751 85 UPPSALA

Download contact information for Lars Lundin at Department of Surgical Sciences; Molecular imaging and medical physics

Publications

Recent publications

Homozygosity for a missense variant in COMP gene associated with severe pseudoachondroplasia

Tariq, M.; Khan, T. N.; Lundin, Lars; Jameel, M. et al.

Part of Clinical Genetics, p. 182-186, 2018
- DOI for Homozygosity for a missense variant in COMP gene associated with severe pseudoachondroplasia
Prospective observational study of 177Lu-DOTA-octreotate therapy in 200 patients with advanced metastasized neuroendocrine tumours (NETs): feasibility and impact of a dosimetry-guided study protocol on outcome and toxicity

Garske, Ulrike; Sandström, Mattias; Fröss-Baron, Katarzyna; Lundin, Lars et al.

Part of European Journal of Nuclear Medicine and Molecular Imaging, p. 970-988, 2018
- DOI for Prospective observational study of 177Lu-DOTA-octreotate therapy in 200 patients with advanced metastasized neuroendocrine tumours (NETs): feasibility and impact of a dosimetry-guided study protocol on outcome and toxicity
- Download full text (pdf) of Prospective observational study of 177Lu-DOTA-octreotate therapy in 200 patients with advanced metastasized neuroendocrine tumours (NETs): feasibility and impact of a dosimetry-guided study protocol on outcome and toxicity

All publications

Articles in journal

Homozygosity for a missense variant in COMP gene associated with severe pseudoachondroplasia

Tariq, M.; Khan, T. N.; Lundin, Lars; Jameel, M. et al.

Part of Clinical Genetics, p. 182-186, 2018
- DOI for Homozygosity for a missense variant in COMP gene associated with severe pseudoachondroplasia
Prospective observational study of 177Lu-DOTA-octreotate therapy in 200 patients with advanced metastasized neuroendocrine tumours (NETs): feasibility and impact of a dosimetry-guided study protocol on outcome and toxicity

Garske, Ulrike; Sandström, Mattias; Fröss-Baron, Katarzyna; Lundin, Lars et al.

Part of European Journal of Nuclear Medicine and Molecular Imaging, p. 970-988, 2018
- DOI for Prospective observational study of 177Lu-DOTA-octreotate therapy in 200 patients with advanced metastasized neuroendocrine tumours (NETs): feasibility and impact of a dosimetry-guided study protocol on outcome and toxicity
- Download full text (pdf) of Prospective observational study of 177Lu-DOTA-octreotate therapy in 200 patients with advanced metastasized neuroendocrine tumours (NETs): feasibility and impact of a dosimetry-guided study protocol on outcome and toxicity